Advertisement

Clindamycin Injection

[21 July 2015]

Products Affected - Description

Clindamycin phosphate intravenous injection, Sagent
150 mg/mL, 2 mL vial, 25 count (NDC 25021-0115-02)
150 mg/mL, 4 mL vial, 25 count (NDC 25021-0115-04)
150 mg/mL, 6 mL vial, 25 count (NDC 25021-0115-06
150 mg/mL, 60 mL bulk vial, single count (NDC 25021-0115-51)
150 mg/mL, 60 mL bulk vial, 1 count (NDC 25021-0115-51)
 
Clindamycin intravenous injection, Sandoz
600 mg/50 mL premixed container, 24 count (NDC 00781-3289-09)
 
Cleocin intravenous injection, Pfizer
150 mg/mL, 4 mL ADD-Vantage vials, 25 count (NDC 00009-3124-03)
150 mg/mL, 6 mL ADD-Vantage vials, 25 count (NDC 00009-3447-03)

Reason for the Shortage

  • Pfizer states the Cleocin Add-Vantage vials are on shortage due to manufacturing delays.
  • Hospira had clindamycin injection on shortage due to manufacturing delays.
  • Sandoz had clindamycin injection on shortage due to increased demand.
  • Sagent has clindamycin injection on shortage due to manufacturing delays.

Available Products

Clindamycin phosphate intravenous injection, Akorn
300 mg/50 mL premixed bottle, 1 count (NDC 17478-0120-50)
600 mg/50 mL premixed bottle, 1 count (NDC 17478-0121-50)
900 mg/50 mL premixed bottle, 1 count (NDC 17478-0122-50)
 
Clindamycin phosphate intravenous injection, Fresenius Kabi
150 mg/mL, 2 mL vial, 25 count (NDC 63323-0282-02)
150 mg/mL, 4 mL vial, 25 count (NDC 63323-0282-04)
150 mg/mL, 60 mL bulk vial, 1 count (NDC 63323-0282-60)
150 mg/mL, 6 mL vial, 25 count (NDC 63323-0282-06)
 
Clindamycin phosphate intravenous injection, Hospira
150 mg/mL, 2 mL ADD-Vantage vial, 25 count (NDC 00409-4053-03)
150 mg/mL, 2 mL vial, 25 count (NDC 00409-4050-01)
150 mg/mL, 4 mL ADD-Vantage vial, 25 count (NDC 00409-4054-03)
150 mg/mL, 4 mL vial, 25 count (NDC 00409-4051-01)
150 mg/mL, 6 mL ADD-Vantage vial, 25 count (NDC 00409-4055-03)
150 mg/mL, 6 mL vial, 25 count (NDC 00409-4052-01)
150 mg/mL, 60 mL bulk vial, 1 count (NDC 00409-4197-01)
 
Clindamycin phosphate intravenous injection, Sandoz
300 mg/50 mL premixed container, 24 count (NDC 00781-3288-09)
900 mg/50 mL premixed container, 24 count (NDC 00781-3290-09)
 
Cleocin intravenous injection, Pfizer
150 mg/mL, 2 mL vial, 25 count (NDC 00009-0870-26)
150 mg/mL, 4 mL vial, 25 count (NDC 00009-0775-26)
150 mg/mL, 6 mL vial, 25 count (NDC 00009-0902-18)
150 mg/mL, 60 mL vial, 5 count (NDC 00009-0728-09)
300 mg/50 mL premixed bags, 24 count (NDC 00009-3381-02)
600 mg/50 mL premixed bags, 24 count (NDC 00009-3375-02)
900 mg/50 mL premixed bags, 24 count (NDC 00009-3382-02)

Estimated Resupply Dates

  • Pfizer has Cleocin 150 mg/mL 4 mL and 6 mL ADD-Vantage vials on back order and the company estimates a release date of April 2016.
  • Sagent has clindamycin 2 mL, 4 mL, 6 mL, and 60 mL vials on back order and the company estimates a release date of October 2015 for the 2 mL, 4 mL, and 6 mL vials, and September 2015 for the 60 mL vials.
  • Sandoz has clindamycin 600 mg/50 mL premixed containers on back order with an estimated release date of late-July 2015.

Related Shortages

Updated

July 21, June 25, April 17 and 30, March 9, 23, and 30, February 12, January 14, 2015; December 5, 17, 22, and 29, November 4 and 24, October 10 and 23, September 3, 12, and 24, August 8 and 15, July 8, June 12, May 5 and 23, April 7 and 23, March 5, 11, and 26, February 10 and 21, January 14 and 24, 2014; December 18 and 27, November 6 and 21, October 7, 14, and 23, September 17, August 7 and 28, July 3, June 13, 2013, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement